Brief: Briacell Announces Successful Completion Of Phase I Portion Of Clinical Study In Advanced Breast Cancer
21/10/2022 14:21
Oct 21 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL ANNOUNCES SUCCESSFUL COMPLETION OF PHASE I
PORTION OF
CLINICAL STUDY IN ADVANCED BREAST CANCER; RANDOMIZED PHASE II
EFFICACY EVALUATION PROGRESSING
* BRIACELL THERAPEUTICS CORP - BRIACELL IS ON SCHEDULE TO
MEET
WITH FDA LATER THIS YEAR TO DISCUSS DESIGN OF A KEY REGISTRATION
STUDY
* BRIACELL THERAPEUTICS CORP - PHASE II EFFICACY PORTION OF
STUDY,
UNDER FDA'S FAST TRACK DESIGNATION, NOW UNDERWAY
Source text for Eikon: ID:nGNX1by2h7
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study